Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration

British Journal of Ophthalmology

Volumn 100, Issue 12, 2016, Pages 1629-1633

  Mansour, Ahmad M ^a,b   Chhablani, Jay ^c   Antonios, Rafic S ^a   Yogi, Rohit ^c   Younis, Muhammad H ^a,b   Dakroub, Rola ^a,b   Chahine, Hasan ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

^c L V PRASAD EYE INSTITUTE   (India)

Author keywords

Macula; Neovascularisation; Retina

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CAUCASIAN; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; ELECTRORETINOGRAPHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INDIAN; INTRAOCULAR PRESSURE; MALE; OFF LABEL DRUG USE; OPTICAL COHERENCE TOMOGRAPHY; OSMOLARITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINAL PIGMENT EPITHELIUM; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; WILCOXON SIGNED RANKS TEST; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; MULTICENTER STUDY; RETINA MACULA LUTEA; TIME FACTOR; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR DEGENERATION; MALE; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84966312381     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2015-308319     Document Type: Article

References (19)

1. Schmid MK, Bachmann LM, Fas L, et al. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol 2015;99:141-6.
2. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014;121:193-201.
3. Chung C, Pherwani N. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer. Am J Health Syst Pharm 2013;70:1887-96.
4. Malik D, Tarek M, Caceres del Carpio J, et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol 2014;98 Suppl 1(Suppl 1):i11-16.
5. de Oliveira Dias JR, Badaró E, Novais EA, et al. Preclinical investigations of intravitreal ziv-aflibercept. Ophthalmic Surg Lasers Imaging Retina 2014;45:577-84.
6. Chhablani J. Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion. Indian J Ophthalmol 2015;63:469-70.
7. de Oliveira Dias JR, Xavier CO, Maia A, et al. Intravitreal injection of ziv-aflibercept in patient with refractory age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina 2015;46:91-4.
8. Videkar C, Kapoor A, Chhablani J, et al. Ziv-aflibercept a novel option for the treatment of polypoidal choroidal vasculopathy. BMJ Case Rep 2015;2015.
9. Chhablani J, Narayanan R, Mathai A, et al. Short-term safety profile of intravitreal ziv-aflibercept. Retina Published Online First: 11 Dec 2015; doi:10.1097/IAE.0000000000000913
10. Mansour AM, Al-Ghadban SI, Yunis MH, et al. Ziv-aflibercept in macular disease. Br J Ophthalmol 2015;99:1055-9.
11. Nagiel A, Sadda SR, Schwartz SD, et al. Resolution of a giant pigment epithelial detachment with half-dose aflibercept. Retin Cases Brief Rep 2015;9:269-72.
12. Ziemssen F, Bertelmann T, Hufenbach U, et al. [Delayed treatment initiation of more than 2 weeks: relevance for possible gain of visual acuity after anti-VEGF therapy under real life conditions (interim analysis of the prospective OCEAN study)]. Ophthalmologe 2016;113:143-51.
13. Lim JH, Wickremasinghe SS, Xie J, et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol 2012;153:678-86.
14. Kim JH, Chang YS, Kim JW, et al. Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization. Ophthalmology 2014;121:926-35.
15. Jain S, Kishore K, Sharma YR. Intravitreal anti-VEGF monotherapy for thick submacular hemorrhage of less than 1 week duration secondary to neovascular age-related macular degeneration. Indian J Ophthalmol 2013;61:490-6.
16. Bailey C, Aloumanis V, Walker B, et al. Stability of preoperative cataract surgery gel in polycarbonate syringes. Int J Pharm Compd 2009;13:564-8.
17. Stein JD, Newman-Casey PA, Mrinalini T, et al. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology 2014;121:936-45.
18. Silver J. Drugs for macular degeneration, price discrimination, and Medicare's responsibility not to overpay. Jama 2014;312:23-4.
19. Raftery J, Clegg A, Jones J, et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007;91:1244-6.